The DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index.
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Open accessAbstract
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in regulation of cell survival, metabolism, growth and protein synthesis in response to upstream signals in both normal physiological and pathological conditions, especially in cancer. Aberrant mTOR signaling resulting from genetic alterations from different levels of the signal cascade is commonly observed in various types of cancers. Upon hyperactivation, mTOR signaling promotes cell proliferation and metabolism that contribute to tumor initiation and progression. In addition, mTOR also negatively regulates autophagy via different ways. We discuss mTOR signaling and its key upstream and downstream factors, the specific genetic changes in the mTOR pathway and the inhibitors of mTOR applied as therapeutic strategies in eight solid tumors. Although monotherapy and combination therapy with mTOR inhibitors have been extensively applied in preclinical and clinical trials in various cancer types, innovative therapies with better efficacy and less drug resistance are still in great need, and new biomarkers and deep sequencing technologies will facilitate these mTOR targeting drugs benefit the cancer patients in personalized therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“Along with this process, mTORC1 is recruited to the lysosomal surface [39,40].”
BackgroundTargeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“Along with this process, mTORC1 is recruited to the lysosomal surface [39,40].”
BackgroundProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M., Böhle, A., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Hernández, V., Kaasinen, E., Palou, J., Rouprêt, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,241
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 2,070
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., Mukherjee, C., Shi, Y., Gélinas, C., Fan, Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.001 · Cited by 2,011
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
Settembre, C., Fraldi, A., Medina, D. L., & Ballabio, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3565 · Cited by 1,697
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
Rho GTPases Control Polarity, Protrusion, and Adhesion during Cell Movement
Nobes, C. D., & Hall, A. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.144.6.1235 · Cited by 1,445
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“p53 also regulates the mTOR pathway by a target gene, DNA damage and development 1 (REDD1), which is essential for hypoxia activation of TSC1/2 and modulated by oxidative stress [159,160].”
BackgroundThe role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Sestrin2 is a leucine sensor for the mTORC1 pathway
Wolfson, R. L., Chantranupong, L., Saxton, R. A., Shen, K., Scaria, S. M., Cantor, J. R., & Sabatini, D. M. (2016) · Science · doi:10.1126/science.aab2674 · Cited by 1,306
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 5×
“Mutation of the p53 gene or deletion of the 17p chromosome is significant for tumor initiation, especially from adenoma to carcinoma in CRC [157,158]. p53 inhibits mTOR activity via AMPK-β1 and TSC2 in CRC cell lines. p53 also regulates the mTOR pathway by a target gene, DNA damage and development 1 (REDD1), which is…”
BackgroundInfluentialThe coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
The Double-Edged Sword of Autophagy Modulation in Cancer
White, E., & DiPaola, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5023 · Cited by 1,138
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,063
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Hierarchical phosphorylation of the translation inhibitor 4E-BP1
Gingras, A.-C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.912401 · Cited by 883
Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 854
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Davis, C. F., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., Buhay, C., Kang, H., Kim, S. C., Fahey, C. C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.014 · Cited by 842
Self-citationLysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
Wang, S., Tsun, Z.-Y., Wolfson, R. L., Shen, K., Wyant, G. A., Plovanich, M. E., Yuan, E. D., Jones, T. D., Chantranupong, L., Comb, W., et al. (2015) · Science · doi:10.1126/science.1257132 · Cited by 824
Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway
Han, J. M., Jeong, S. J., Park, M. C., Kim, G., Kwon, N. H., Kim, H. K., Ha, S. H., Ryu, S. H., & Kim, S. (2012) · Cell · doi:10.1016/j.cell.2012.02.044 · Cited by 824
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
HIF and c-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and Proliferation
Gordan, J. D., Thompson, C. B., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.006 · Cited by 803
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M., & Manning, B. D. (2016) · Science · doi:10.1126/science.aad0489 · Cited by 795
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1
Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726
p53 status determines the role of autophagy in pancreatic tumour development
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., Au, A., Rai, T. S., Zheng, L., Ridgway, R., et al. (2013) · Nature · doi:10.1038/nature12865 · Cited by 713
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
mTORC1 signaling and the metabolic control of cell growth
Ben-Sahra, I., & Manning, B. D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.012 · Cited by 644
McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 640
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 1×
“Except for the above, mTOR signaling hyper-activation can commonly result from mutations of upstream genes including oncogenes and tumor suppressor genes [75].”
BackgroundSelf-citationRoock, W. D., Vriendt, V. D., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 603
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Initiating Cellular Stress Responses
Bakkenist, C. J., & Kastan, M. B. (2004) · Cell · doi:10.1016/j.cell.2004.06.023 · Cited by 544
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Self-citationPeterson, R. T., Desai, B. N., Hardwick, J. S., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4438 · Cited by 486
Ohtsu, A., Ajani, J. A., Bai, Y.-X., Bang, Y.-J., Chung, H.-C., Pan, H.-M., Sahmoud, T., Shen, L., Yeh, K.-H., Chin, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3552 · Cited by 483
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., & Haber, D. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00706-2 · Cited by 474
Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 469
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 464
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng, D., Hu, R. H., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., Vinson, V. L., Gumpper, K. L., et al. (1997) · PubMed · Cited by 463
PTEN: Multiple Functions in Human Malignant Tumors
Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 463
The utilization of extracellular proteins as nutrients is suppressed by mTORC1
Palm, W., Park, Y., Wright, K., Pavlova, N. N., Tuveson, D. A., & Thompson, C. B. (2015) · Cell · doi:10.1016/j.cell.2015.06.017 · Cited by 457 · cited 1×
“Besides, mTORC1 inhibition can also promote cell proliferation by catabolism of extracellular proteins in nutrient deprived conditions, and enhance cell survival via autophagy [293,294].”
BackgroundSun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 450
mTORC1 and mTORC2 in cancer and the tumor microenvironment
Kim, L. C., Cook, R. S., & Chen, J. (2017) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 444
Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2
Humphrey, S. J., Yang, G., Yang, P., Fazakerley, D. J., Stöckli, J., Yang, J. Y., & James, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.010 · Cited by 411
Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
PtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase Complex
Liu, P., Gan, W., Chin, Y. R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L. C., Toker, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0460 · Cited by 382
Self-citationPDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28984 · Cited by 381
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., Cordon-Cardo, C., Celeste Simon, M., Rafii, S., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature05029 · Cited by 378
Chang, L., Graham, P. H., Hao, J., Ni, J., Bucci, J., Cozzi, P. J., Kearsley, J. H., & Li, Y. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.407 · Cited by 377
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Leucyl-tRNA Synthetase Controls TORC1 via the EGO Complex
Bonfils, G., Jaquenoud, M., Bontron, S., Ostrowicz, C., Ungermann, C., & De Virgilio, C. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.009 · Cited by 340
Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
Carrière, A., Cargnello, M., Julien, L.-A., Gao, H., Bonneil, É., Thibault, P., & Roux, P. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.07.078 · Cited by 336
Inactivation of p53 and Pten promotes invasive bladder cancer
Puzio-Kuter, A. M., Castillo-Martin, M., Kinkade, C. W., Wang, X., Shen, T. H., Matos, T., Shen, M. M., Cordon-Cardo, C., & Abate-Shen, C. (2009) · Genes & Development · doi:10.1101/gad.1772909 · Cited by 329
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 301
mTOR Pathways in Cancer and Autophagy
Paquette, M., El-Houjeiri, L., & Pause, A. (2018) · Cancers · doi:10.3390/cancers10010018 · Cited by 297
A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Yang, G., Murashige, D. S., Humphrey, S. J., & James, D. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.016 · Cited by 295
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Morgan, T., Koreckij, T., & Corey, E. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787580999 · Cited by 283
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
Ricoult, S. J. H., Yecies, J. L., Ben-Sahra, I., & Manning, B. D. (2016) · Oncogene · doi:10.1038/onc.2015.179 · Cited by 281
Bakker, W. J., Harris, I. S., & Mak, T. W. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.10.035 · Cited by 277
Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Baselga, J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-12 · Cited by 261
Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 259
Browne, G. J., & Proud, C. G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2986-2997.2004 · Cited by 256
Masri, J., Bernath, A., Martin, J., Jo, O. D., Vartanian, R., Funk, A., & Gera, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2223 · Cited by 253
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Platt, F. M., Hurst, C. D., Taylor, C. F., Gregory, W. M., Harnden, P., & Knowles, M. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0898 · Cited by 251
on behalf of the Transatlantic Prostate Group, Reid, A. H. M., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605554 · Cited by 250
Molecular Biology of Lung Cancer
Nana-Sinkam, S. P., & Powell, C. A. (2013) · Chest · doi:10.1378/chest.12-2346 · Cited by 248
Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer
Johnson, S. M., Gulhati, P., Rampy, B. A., Han, Y., Rychahou, P. G., Doan, H. Q., Weiss, H. L., & Evers, M. B. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.008 · Cited by 247
PTEN Level in Tumor Suppression: How Much Is Too Little?
Carracedo, A., Alimonti, A., & Pandolfi, P. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2488 · Cited by 246
Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses García, A., Raimondi, A. R., Jufe, R., Itoiz, M., Gao, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1041 · Cited by 243
Fonseca, B. D., Smith, E. M., Lee, V. H.-Y., MacKintosh, C., & Proud, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704406200 · Cited by 240
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi, Y., Gera, J., Hu, L., Hsu, J.-H., Bookstein, R., Li, W., & Lichtenstein, A. K. (2002) · PubMed · Cited by 231
Bahrami, A., Khazaei, M., Hasanzadeh, M., ShahidSales, S., Joudi Mashhad, M., Farazestanian, M., Sadeghnia, H. R., Rezayi, M., Maftouh, M., Hassanian, S. M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25950 · Cited by 230
Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L., Lesnick, J. D., Lewis, C., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 229
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 228
Thomanetz, V., Angliker, N., Cloëtta, D., Lustenberger, R. M., Schweighauser, M., Oliveri, F., Suzuki, N., & Rüegg, M. A. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201205030 · Cited by 221
Lechner, M., Frampton, G. M., Fenton, T., Feber, A., Palmer, G., Jay, A., Pillay, N., Forster, M., Cronin, M. T., Lipson, D., et al. (2013) · Genome Medicine · doi:10.1186/gm453 · Cited by 217
Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin
Huffman, T. A., Mothe-Satney, I., & Lawrence, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022634399 · Cited by 215
Doi, T., Muro, K., Boku, N., Yamada, Y., Nishina, T., Takiuchi, H., Komatsu, Y., Hamamoto, Y., Ohno, N., Fujita, Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2923 · Cited by 215
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214
Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., Marshall, B., Speicher, L., Moore, L., & Rowinsky, E. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0118 · Cited by 212
Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K.-A., Sangai, T., Adkins, F., Gonzalez-Angulo, A. M., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 208
Graff, J. R., Konicek, B. W., Lynch, R. L., Dumstorf, C. A., Dowless, M. S., McNulty, A. M., Parsons, S. H., Brail, L. H., Colligan, B. M., Koop, J. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3472 · Cited by 202
Woo, S.-Y., Kim, D.-H., Jun, C.-B., Kim, Y.-M., Haar, E. V., Lee, S.-I., Hegg, J. W., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704343200 · Cited by 202
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Willems, L., Tamburini, J., Chapuis, N., Lacombe, C., Mayeux, P., & Bouscary, D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0227-y · Cited by 201
Amato, R. J., Jac, J., Giessinger, S., Saxena, S., & Willis, J. P. (2009) · Cancer · doi:10.1002/cncr.24280 · Cited by 201
Umemura, S., Mimaki, S., Makinoshima, H., Tada, S., Ishii, G., Ohmatsu, H., Niho, S., Yoh, K., Matsumoto, S., Takahashi, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000250 · Cited by 200
Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198
mTOR function and therapeutic targeting in breast cancer.
Hare, S. H., & Harvey, A. (2017) · PubMed · Cited by 189
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
Weiler, M., Blaes, J., Pusch, S., Sahm, F., Czabanka, M., Luger, S., Bunse, L., Solecki, G., Eichwald, V., Jugold, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314469111 · Cited by 188
mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets
Watanabe, R., Wei, L., & Huang, J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089623 · Cited by 186
Freudlsperger, C., Burnett, J. R., Friedman, J. A., Kannabiran, V. R., Chen, Z., & Van Waes, C. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.541440 · Cited by 183
deGraffenried, L. A., Fulcher, L., Friedrichs, W. E., Grünwald, V., Ray, R. B., & Hidalgo, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh388 · Cited by 177
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173
mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
Molinolo, A. A., Marsh, C., El Dinali, M., Gangane, N., Jennison, K., Hewitt, S., Patel, V., Seiwert, T. Y., & Gutkind, J. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2824 · Cited by 173
The mTOR Pathway: A New Target in Cancer Therapy
Ciuffreda, L., Di Sanza, C., Incani, U. C., & Milella, M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517172 · Cited by 170
Lang, S. A., Gaumann, A., Koehl, G. E., Seidel, U., Bataille, F., Klein, D., Ellis, L. M., Bolder, U., Hofstaedter, F., Schlitt, H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22442 · Cited by 169
Phase II study of everolimus in metastatic urothelial cancer
Milowsky, M. I., Iyer, G., Regazzi, A. M., Al‐Ahmadie, H., Gerst, S. R., Ostrovnaya, I., Gellert, L. L., Kaplan, R., Garcia‐Grossman, I. R., Pendse, D., et al. (2013) · BJU International · doi:10.1111/j.1464-410x.2012.11720.x · Cited by 166
Gan, X., Wang, J., Wang, C., Sommer, E., Kozasa, T., Srinivasula, S., Alessi, D., Offermanns, S., Simon, M. I., & Wu, D. (2012) · Nature Cell Biology · doi:10.1038/ncb2507 · Cited by 163
Soria, J.-C., Shepherd, F. A., Douillard, J.-Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp060 · Cited by 163
Wislez, M., Spencer, L., Izzo, J. G., Juroske, D. M., Balhara, K. S., CODY, D. D., Price, R. E., Hittelman, W. N., Wistuba, I. I., & Kurie, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4420 · Cited by 163
Status of PI3K inhibition and biomarker development in cancer therapeutics
Markman, B., Atzori, F., Pérez-García, J., Tabernero, J., & Baselga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp347 · Cited by 159
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., & Milella, M. (2018) · Cancers · doi:10.3390/cancers10010023 · Cited by 157
Yu, G., Wang, J., Chen, Y., Wang, X., Pan, J., Li, G., Jia, Z., Li, Q., Yao, J. C., & Xie, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2138 · Cited by 156
Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A., & Lawrence, J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5033 · Cited by 152
PTEN Deficiency Contributes to the Development and Progression of Head and Neck Cancer
SQUARIZE, C. H., CASTILHO, R. M., Abrahão, A. C., Molinolo, A., Lingen, M. W., & Gutkind, J. S. (2013) · Neoplasia · doi:10.1593/neo.121024 · Cited by 152
Puertollano, R. (2014) · F1000Prime Reports · doi:10.12703/p6-52 · Cited by 149
Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
Roper, J., Richardson, M. P., Wang, W. V., Richard, L. G., Chen, W., Coffee, E. M., Sinnamon, M. J., Lee, L., Chen, P., Bronson, R. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025132 · Cited by 147
Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer
Patel, V., Marsh, C. A., Dorsam, R. T., Mikelis, C. M., Masedunskas, A., Amornphimoltham, P., Nathan, C. O., Singh, B., Weigert, R., Molinolo, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3192 · Cited by 144
The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
Riquelme, I., Tapia, Ó., Espinoza, J. A., Leal, P., Buchegger, K., Sandoval, A., Bizama, C., Araya, J. C., Peek, R. M., & Roa, J. C. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0066-5 · Cited by 141
Templeton, A. J., Dutoit, V., Cathomas, R. L., Rothermundt, C. A., Bärtschi, D., Droege, C., Gautschi, O. P., Borner, M., Fechter, E., Stenner, F., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.040 · Cited by 140
Emerging therapeutic targets in bladder cancer
Carneiro, B. A., Meeks, J. J., Kuzel, T. M., Scaranti, M., Abdulkadir, S. A., & Giles, F. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.11.003 · Cited by 140
Genetic variations of mTORC1 genes and risk of gastric cancer in an eastern chinese population
He, J., Wang, M., Qiu, L., Zhu, M., Shi, T., Zhou, X., Sun, M., Yang, Y., Wang, J., Jin, L., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22013 · Cited by 140
Huang, J., Wu, S., Wu, C., & Manning, B. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0975 · Cited by 138
Seront, E., Rottey, S., Sautois, B. R., Kerger, J. N., D'Hondt, L. A., Verschaeve, V., Canon, J. L., Dopchie, C., Vandenbulcke, J., Whenham, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds057 · Cited by 137
Guichard, S. M., Curwen, J., Bihani, T., D’Cruz, C. M., Yates, J. W. T., Grondine, M. R., Howard, Z., Davies, B. R., Bigley, G., Klinowska, T. C. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0365 · Cited by 133
Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells
Skvortsova, I., Skvortsov, S., Stasyk, T., Raju, U., Popper, B., Schiestl, B., von Guggenberg, E., Neher, A., Bonn, G. K., Huber, L. A., et al. (2008) · PROTEOMICS · doi:10.1002/pmic.200800113 · Cited by 133
The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet, F., Attalla, K., & Sfakianos, J. P. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.02.017 · Cited by 133
Garcia, J. A., & Danielpour, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2408 · Cited by 131
Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer
Zhang, J., Roberts, T. M., & Shivdasani, R. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.010 · Cited by 130
Self-citationSchmitz, M., Grignard, G., Margue, C., Dippel, W., Capesius, C., Mossong, J., Nathan, M., Giacchi, S., Scheiden, R., & Kieffer, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22359 · Cited by 126
mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer
Zhang, Y., Dai, Q., Sun, D., Xiong, H., Tian, X., Gao, F., Xu, M., Chen, G., Han, Z., & Fang, J. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0555-9 · Cited by 126
Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma
Kucejová, B., Peña‐Llopis, S., Yamasaki, T., Sivanand, S., Tran, T. A. T., Alexander, S., Wolff, N. C., Lotan, Y., Xie, X.-J., Kabbani, W., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0302 · Cited by 126
Sjödahl, G., Lauss, M., Guðjónsson, S., Liedberg, F., Halldén, C., Chebil, G., Månsson, W., Höglund, M., & Lindgren, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018583 · Cited by 119
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0971 · Cited by 116
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
Manfredi, G. I., Dicitore, A., Gaudenzi, G., Caraglia, M., Persani, L., & Vitale, G. (2014) · Endocrine · doi:10.1007/s12020-014-0380-1 · Cited by 110
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Metadata
- Authors
- Tian, T., Li, X., & Zhang, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-11
- Volume
- 20
- Issue
- 3
- Pages
- 755
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2911580600
- Cited by
- 576
- References
- 286
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.